Chief Commercial Officer — Mature-Brands Division

The mandate

A mature-brands division has acquired regional rights to a medicine that requires a different specialist, payer and patient pathway from its established portfolio. The transaction case assumes use of existing country infrastructure, yet launch readiness varies and legacy incentives favour current brands. The CCO is departing. An urgent replacement must build the new launch without destabilising profitable mature operations.

Approximately 550 employees and material partners support commercial, market access, distribution, customer operations, data and partnerships from Singapore across the wider region. The CCO owns commercial strategy, country execution, pricing, market access, partnerships, forecasting and commercial operations, reporting to the Group Chief Executive or nominated sponsor. Medical, regulatory and safety functions retain independent authority.

The first task is a launch-capability gap by market. Specialist centres, diagnosis, payer route, distribution, approved content, trained teams and patient support must be evidenced. The CCO will distinguish reusable infrastructure from superficial overlap. A field force calling on different customers is not automatically launch capacity.

The acquired rights and handover need commercial translation. Customer history, market research, contracts, forecasts and content may transfer under limitations. The CCO will verify provenance, permitted use and quality rather than accept the seller's materials as launch-ready. Relationship hand-offs require consent and clear ownership.

Country sequence should follow access and execution. Early approval may not justify launch where reimbursement, diagnostics or supply are missing. Smaller markets may be attractive through partners. The CCO will recommend build, partner, stage or defer choices with total pathway economics.

Pricing and access will reflect local comparators and evidence. The leader will prevent a global value assumption from becoming an unsupported country price. Discounts, risk-sharing or patient support need measurable obligations and data capability. Reference-pricing effects will inform sequence.

Mature-brand cash must remain visible. Redirecting leaders and budgets to the new medicine can weaken established products more than forecast. The CCO will define minimum commercial, supply and customer coverage by brand and market, simplifying where evidence supports it. Launch investment should be funded through explicit decisions, not uncontrolled erosion.

Commercial organisation design will avoid two parallel cultures. Portfolio teams may share account, data and operations while requiring different scientific and customer capability. The CCO will set decision rights, incentives and training so new-launch enthusiasm does not marginalise mature obligations or blur promotional boundaries.

Forecasting will use patient and access drivers. Eligible population, diagnosis, centre activation, reimbursement, initiation and persistence should create the launch range. Mature-brand forecasts will include tender, channel inventory and competitor entry. Assumptions should be common across finance, supply and countries.

Distribution and product availability require commercial ownership. Channel partners need service, inventory, returns, complaint and safety routes. The CCO will ensure launch stock reflects access and avoids loading. Mature products should not suffer service decline because distributor attention shifts.

Patient programmes must solve a defined barrier. Consent, vendor, eligibility, data, safety and exit will be governed. The CCO will not approve programmes designed mainly to drive demand or compensate for an unsuitable payer proposition. Outcomes and operating cost will be measured.

Commercial content and conduct controls will be strengthened. Acquired material requires local review; mature brands remain subject to current evidence. Agencies, distributors and field teams need approved channels and monitoring. Revenue performance will not excuse unapproved claims or inappropriate inducement.

The replacement leader will complete relationship and knowledge transfer from the incumbent and rights seller. Priority markets and partners need more than one accountable contact. Commercial leaders will be assessed on portfolio delivery, evidence and collaboration, with succession developed through actual country decisions.

What you will own

• New-medicine launch and mature-brand commercial strategy.
• Country readiness, sequence and partner choices.
• Rights handover, pricing and market access.
• Portfolio investment and minimum brand coverage.
• Organisation, incentive and commercial capability.
• Forecasting, distribution and patient programmes.
• Content, conduct and partner governance.
• Commercial succession and relationship transfer.

The first 12 months

Within 30 days, validate market gaps, acquired materials and incumbent relationships. Protect any mature-brand obligation weakened by diverted attention and decide immediate launch blockers.

By month five, approve market sequence, pricing routes, partner model and portfolio organisation. Certify first-wave teams and complete operational simulations.

At twelve months, deliver first-wave launch within approved dates and spend, secure planned access in at least 80% of priority markets and retain mature-brand contribution within 5% of adjusted forecast. No launch market should activate without approved content, qualified distribution and safety intake, while channel inventory remains within agreed demand ranges.

What the sponsor will examine

• Existing infrastructure tested for real launch fit.
• Acquired materials verified before use.
• Country sequence reflecting access and reference effects.
• Mature-brand cash protected through explicit coverage.
• Patient programmes solving evidenced barriers.
• Relationships and capability transferred beyond individuals.

The person

You bring 22–28 years in pharmaceutical commercial leadership, including CCO or regional portfolio authority in Asian markets. Your record includes acquired-rights launch, mature brands, pricing, distribution, partnerships and country execution.

Candidates must demonstrate how they launched a new medicine without allowing the established portfolio to deteriorate and a market they deferred despite approval. Singapore is the hybrid base, with substantial regional travel.

Compensation and terms

Base compensation is SGD 600,000–850,000 plus annual incentive and long-term participation linked to launch, access, portfolio contribution, compliance and leadership. The permanent hybrid Singapore appointment reports to the Group Chief Executive or nominated executive-committee sponsor. Replacement is urgent before first-wave commitments.

Confidentiality

The enterprise, acquired rights, products, markets, prices, partners, customers and launch plans remain confidential. Further information follows conflicts and signed confidentiality. Applicants must not contact pharmaceutical companies or distributors to infer the client.